Cargando…
Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020 : workshop summary /
"There is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timel...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores Corporativos: | , |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press,
©2012.
|
| Colección: | Online access: National Academy of Sciences National Academies Press.
Online access: NCBI NCBI Bookshelf. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | EBSCO_ocn933721289 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 120507s2012 dcua ob 000 0 eng d | ||
| 010 | |a 2012474101 | ||
| 040 | |a VT2 |b eng |e pn |c VT2 |d OCLCO |d OCLCQ |d AZK |d OCLCF |d OCLCQ |d OCLCA |d U3W |d UUM |d OCLCO |d OCL |d COCUF |d OCLCA |d AU@ |d OCLCO |d MOR |d CCO |d PIFAG |d STF |d WRM |d NRAMU |d OCLCA |d UKAHL |d UKCRE |d BOL |d LVT |d OCLCO |d OCLCQ |d OCL |d N$T | ||
| 019 | |a 961678200 |a 971089030 |a 988442146 |a 1077359285 |a 1081276796 |a 1097091664 |a 1114409919 |a 1153549876 |a 1156336598 |a 1229671170 |a 1249234404 | ||
| 020 | |a 9780309253154 | ||
| 020 | |a 0309253152 | ||
| 020 | |a 0309253160 | ||
| 020 | |a 9780309253161 |q (electronic bk.) | ||
| 035 | |a (OCoLC)933721289 |z (OCoLC)961678200 |z (OCoLC)971089030 |z (OCoLC)988442146 |z (OCoLC)1077359285 |z (OCoLC)1081276796 |z (OCoLC)1097091664 |z (OCoLC)1114409919 |z (OCoLC)1153549876 |z (OCoLC)1156336598 |z (OCoLC)1229671170 |z (OCoLC)1249234404 | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a R853.C55 | |
| 060 | 4 | |a QV 771.4 | |
| 082 | 0 | 4 | |a 610.72/4 |2 22 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Envisioning a transformed clinical trials enterprise in the United States : |b establishing an agenda for 2020 : workshop summary / |c Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, Rapporteurs ; Forum on Drug Discovery, Development, and Translation ; Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| 260 | |a Washington, D.C. : |b National Academies Press, |c ©2012. | ||
| 300 | |a 1 online resource (xvi, 232 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 340 | |g polychrome. |2 rdacc |0 http://rdaregistry.info/termList/RDAColourContent/1003 | ||
| 347 | |a text file |2 rdaft |0 http://rdaregistry.info/termList/fileType/1002 | ||
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise. | |
| 520 | |a "There is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and practical evidence for drug development and to support medical treatment decisions. With the need for transforming the CTE in the U.S. becoming more pressing, the IOM Forum on Drug Discovery, Development, and Translation held a two-day workshop in November 2011, bringing together leaders in research and health care. The workshop focused on how to transform the CTE and discussed a vision to make the enterprise more efficient, effective, and fully integrated into the health care system. Key issue areas addressed at the workshop included: the development of a robust clinical trials workforce, the alignment of cultural and financial incentives for clinical trials, and the creation of a sustainable infrastructure to support a transformed CTE. This document summarizes the workshop"--Publisher's description. | ||
| 588 | 0 | |a Print version record. | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Clinical trials |z United States. | |
| 650 | 0 | |a Clinical trials |x Economic aspects |z United States. | |
| 650 | 0 | |a Clinical trials |x Social aspects |z United States. | |
| 650 | 0 | |a Drug development |z United States. | |
| 650 | 0 | |a Drugs |x Testing. | |
| 650 | 0 | |a Pharmaceutical industry |z United States. | |
| 650 | 0 | |a Business and medicine |z United States. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 0 | |a Pharmaceutical industry. | |
| 650 | 2 | 2 | |a Randomized Controlled Trials as Topic |z United States |v Congresses. |
| 650 | 1 | 2 | |a Clinical Trials as Topic |z United States |v Congresses. |
| 650 | 1 | 2 | |a Drug Design |z United States |v Congresses. |
| 650 | 2 | 2 | |a Drug Industry |z United States |v Congresses. |
| 650 | 1 | 2 | |a Clinical Trials as Topic |
| 650 | 1 | 2 | |a Drug Design |
| 650 | 2 | 2 | |a Randomized Controlled Trials as Topic |
| 650 | 2 | 2 | |a Drug Industry |
| 651 | 2 | |a United States | |
| 650 | 6 | |a Études cliniques |z États-Unis. | |
| 650 | 6 | |a Études cliniques |x Aspect économique |z États-Unis. | |
| 650 | 6 | |a Études cliniques |x Aspect social |z États-Unis. | |
| 650 | 6 | |a Médicaments |x Développement |z États-Unis. | |
| 650 | 6 | |a Médicaments |x Essais cliniques. | |
| 650 | 6 | |a Industrie pharmaceutique |z États-Unis. | |
| 650 | 6 | |a Affaires et médecine |z États-Unis. | |
| 650 | 6 | |a Médicaments |x Conception. | |
| 650 | 6 | |a Industrie pharmaceutique. | |
| 650 | 7 | |a Drugs |x Design. |2 fast |0 (OCoLC)fst00898790 | |
| 650 | 7 | |a Pharmaceutical industry. |2 fast |0 (OCoLC)fst01060129 | |
| 650 | 7 | |a Drugs |x Testing. |2 fast |0 (OCoLC)fst00898940 | |
| 650 | 7 | |a Drug development. |2 fast |0 (OCoLC)fst00898670 | |
| 650 | 7 | |a Business and medicine. |2 fast |0 (OCoLC)fst01742132 | |
| 650 | 7 | |a Clinical trials. |2 fast |0 (OCoLC)fst00864429 | |
| 651 | 7 | |a United States. |2 fast |0 (OCoLC)fst01204155 | |
| 655 | 7 | |a Conference papers and proceedings. |2 fast |0 (OCoLC)fst01423772 | |
| 655 | 2 | |a Congress | |
| 655 | 7 | |a Conference papers and proceedings. |2 lcgft | |
| 655 | 7 | |a Actes de congrès. |2 rvmgf | |
| 700 | 1 | |a Weisfeld, Neil E. | |
| 700 | 1 | |a English, Rebecca A. | |
| 700 | 1 | |a Claiborne, Anne B. | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Forum on Drug Discovery, Development, and Translation. | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Board on Health Sciences Policy. | |
| 776 | 0 | 8 | |i Print version: |t Envisioning a transformed clinical trials enterprise in the United States. |d Washington, D.C. : National Academies Press, ©2012 |z 9780309253154 |w (DLC) 2012474101 |
| 830 | 0 | |a Online access: National Academy of Sciences National Academies Press. | |
| 830 | 0 | |a Online access: NCBI NCBI Bookshelf. | |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=991060 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36617548 | ||
| 938 | |a EBSCOhost |b EBSC |n 991060 | ||
| 994 | |a 92 |b IZTAP | ||